Global Amifostine Hydrate Market Size, Share and Trends Analysis Report, By Type (400mg/Dose, 500mg/Dose), By Application (Ovarian Cancer Adjuvant Therapy, Head and Neck Cancer Adjuvant Therapy, and Other), Forecast (2022-2028)

The global amifostine hydrate market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The global amifostine hydrate market growth is attributed to a rise in the number of age-related diseases across the globe. Other major factors driving the growth of the active pharmaceutical ingredient industry include rising incidences of oncology diseases, cardiovascular diseases, diabetes, and an increase in the number of hospitals and diagnostic centers.

According to the most recent research citations presented by the World Health Organization (WHO), cancer is the second leading cause of death worldwide, affecting approximately one in every six people. Amifostine Hydrate is essential in reducing nephrotoxicity and xerostomia caused by chemotherapy and radiation therapy. Due to its cytoprotective activity, amifostine hydrate is the most commonly prescribed adjuvant therapy by oncologists.

Amifostine hydrate is available in a 500mg single dose vial for intravenous administration; it must be reconstituted with 9.7 ml of sodium chloride (0.9 percent) injection. The reconstituted mixture is stable at room temperature for 5 hours and in the refrigerator for 24 hours. It must be administered 30 minutes before chemotherapy, and blood pressure must be continuously monitored every 5 minutes during the infusion. The recommended dose to reduce cumulative renal toxicity is 910 mg/m2 given once daily as a 15-minute infusion 30 minutes before chemotherapy, and blood pressure should be monitored every 5 minutes during the infusion. The usual dose for xerostomia is 200 mg/m2 once a day. The increasing demand for amifostine hydrate in cancer treatment is driving the global amifostine hydrate market.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Clinigen Group, Sun Pharmaceutical Ind. Ltd., Taj Pharmaceuticals, Merro Pharmaceutical Co. Ltd., Luye Pharma Group, Mingren Pharma Inc., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Amifostine Hydrate Market Report by Segment

By Type

• 400mg/Dose
• 500mg/Dose

By Application

• Ovarian Cancer Adjuvant Therapy
• Head and Neck Cancer Adjuvant Therapy
• Other

Global Amifostine Hydrate Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa